Krüppel-like factors in cancer

Nature Reviews Cancer

Volumn 13, Issue 10, 2013, Pages 701-713

  Tetreault, Marie Pier ^a   Yang, Yizeng ^a   Katz, Jonathan P ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; BETA CATENIN; CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 2B; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; FLUOROURACIL; GELATINASE B; I KAPPA B; KRUPPEL LIKE FACTOR; KRUPPEL LIKE FACTOR 10; KRUPPEL LIKE FACTOR 11; KRUPPEL LIKE FACTOR 12; KRUPPEL LIKE FACTOR 13; KRUPPEL LIKE FACTOR 17; KRUPPEL LIKE FACTOR 2; KRUPPEL LIKE FACTOR 3; KRUPPEL LIKE FACTOR 4; KRUPPEL LIKE FACTOR 5; KRUPPEL LIKE FACTOR 6; KRUPPEL LIKE FACTOR 8; KRUPPEL LIKE FACTOR 9; MITOGEN ACTIVATED PROTEIN KINASE 1; NOTCH1 RECEPTOR; PROTEIN P15; PROTEIN P27; PROTEIN P53; RAS PROTEIN; TRANSCRIPTION FACTOR FKHR; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACETYLATION; ANGIOGENESIS; APOPTOSIS; BLADDER CANCER; BONE CANCER; BRAIN CANCER; BREAST CANCER; CANCER GROWTH; CANCER STEM CELL; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; COLON CANCER; DNA BINDING; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; ESOPHAGUS CANCER; GASTROINTESTINAL STROMAL TUMOR; HEAD AND NECK CANCER; HUMAN; HYPOPHYSIS TUMOR; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; INTESTINE CANCER; KIDNEY CANCER; LEUKEMIA; LIVER CANCER; LUNG CANCER; LYMPHOMA; MELANOMA; METASTASIS; MULTIPLE MYELOMA; NEOPLASM; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; SKIN CANCER; TRANSLATIONAL RESEARCH; TUMOR MICROENVIRONMENT; UPREGULATION; UTERINE CERVIX CANCER;

ANIMALS; APOPTOSIS; CELL CYCLE; CELL DIFFERENTIATION; CELL DIVISION; CELL MOVEMENT; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HUMANS; INFLAMMATION; KRUPPEL-LIKE TRANSCRIPTION FACTORS; MICE; NEOPLASM METASTASIS; NEOPLASM PROTEINS; NEOPLASMS; NEOPLASTIC STEM CELLS; ONCOGENES; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSCRIPTION, GENETIC; TUMOR MICROENVIRONMENT; ZINC FINGERS;

EID: 84884567199     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc3582     Document Type: Review

References (203)

1. Miller, I. J. & Bieker, J. J. A novel, erythroid cell-specific murine transcription factor that binds to the CACCC element and is related to the Kruppel family of nuclear proteins. Mol. Cell. Biol. 13, 2776-2786 (1993). This is the identification of the founding member of the KLF family, erythroid Krüpel-like factor KLF1, named for its homology to the Drosophila melanogaster protein Krüpel.
2. McConnell, B. B. & Yang, V. W. Mammalian Kruppel-like factors in health and diseases. Physiol. Rev. 90, 1337-1381 (2010). This is an excellent overview of KLFs and their functional regulation.
3. Yamanaka, S. Strategies and new developments in the generation of patient-specific pluripotent stem cells. Cell Stem Cell 1, 39-49 (2007).
4. Jiang, J. et al. A core Klf circuitry regulates self-renewal of embryonic stem cells. Nature Cell Biol. 10, 353-360 (2008). KLFs have redundant functions and can compensate for KLF4 loss in pluripotency.
5. Yang, Y. & Katz, J. P. in The Biology of Krüppel-like Factors (eds. Nagai, R. F., Friedman, S. L. & Kasuga, M.) 67-82 (Springer, 2009).
6. Dereeper, A. et al. Phylogeny.fr: robust phylogenetic analysis for the non-specialist. Nucleic Acids Res. 36, W465-W469 (2008).
7. Camacho-Vanegas, O. et al. Shaking the family tree: identification of novel and biologically active alternatively spliced isoforms across the KLF family of transcription factors. FASEB J. 27, 432-436 (2013).
8. Yang, Y., Tarapore, R. S., Jarmel, M. H., Tetreault, M. P. & Katz, J. P. p53 mutation alters the effect of the esophageal tumor suppressor KLF5 on keratinocyte proliferation. Cell Cycle 11, 4033-4039 (2012).
9. Rowland, B. D., Bernards, R. & Peeper, D. S. The KLF4 tumour suppressor is a transcriptional repressor of p53 that acts as a context-dependent oncogene. Nature Cell Biol. 7, 1074-1082 (2005). p21 can act as a molecular switch for KLF4 oncogenic function in breast cancers.
10. Fernandez-Zapico, M. E. et al. An mSin3A interaction domain links the transcriptional activity of KLF11 with its role in growth regulation. EMBO J. 22, 4748-4758 (2003). The SIN3A interacting domain is crucial for KLF11 repressive function in cell growth and neoplastic transformation, providing a mechanism by which some KLFs function predominantly as transcriptional activators, whereas others are mainly repressors.
11. Ellenrieder, V. et al. KLF11 mediates a critical mechanism in TGF-beta signaling that is inactivated by Erk-MAPK in pancreatic cancer cells. Gastroenterology 127, 607-620 (2004).
12. Yang, Y. et al. Loss of transcription factor KLF5 in the context of p53 ablation drives invasive progression of human squamous cell cancer. Cancer Res. 71, 6475-6484 (2011). This paper and reference 8 demonstrate that p53 can act as a molecular switch for KLF5 function in proliferation and transformation.
13. Costa, R. H. FoxM1 dances with mitosis. Nature Cell Biol. 7, 108-110 (2005).
14. Yang, W. T. & Zheng, P. S. Kruppel-like factor 4 functions as a tumor suppressor in cervical carcinoma. Cancer 118, 3691-3702 (2012).
15. Ohnishi, S. et al. Downregulation and growth inhibitory effect of epithelial-type Kruppel-like transcription factor KLF4, but not KLF5, in bladder cancer. Biochem. Biophys. Res. Commun. 308, 251-256 (2003).
16. Li, Q. et al. Dysregulated Kruppel-like factor 4 and vitamin D receptor signaling contribute to progression of hepatocellular carcinoma. Gastroenterology 143, 799-810 e1-2 (2012).
17. Zhang, N. et al. Kruppel-like factor 4 negatively regulates beta-catenin expression and inhibits the proliferation, invasion and metastasis of gastric cancer. Int. J. Oncol. 40, 2038-2048 (2012).
18. Chen, Z. Y., Shie, J. L. & Tseng, C. C. Gut-enriched Kruppel-like factor represses ornithine decarboxylase gene expression and functions as checkpoint regulator in colonic cancer cells. J. Biol. Chem. 277, 46831-46839 (2002).
19. Gamper, A. M. et al. Regulation of KLF4 turnover reveals an unexpected tissue-specific role of pVHL in tumorigenesis. Mol. Cell 45, 233-243 (2012).
20. Yu, T. et al. Regulation of the potential marker for intestinal cells, Bmi1, by beta-catenin and the zinc finger protein KLF4: implications for colon cancer. J. Biol. Chem. 287, 3760-3768 (2012).
21. Shum, C. K. et al. Kruppel-like factor 4 (KLF4) suppresses neuroblastoma cell growth and determines non-tumorigenic lineage differentiation. Oncogene http://dx.doi.org/10.1038/onc.2012.437 (2012).
22. Nakahara, Y. et al. Genetic and epigenetic inactivation of Kruppel-like factor 4 in medulloblastoma. Neoplasia 12, 20-27 (2010).
23. Hu, W. et al. Putative tumor-suppressive function of Kruppel-like factor 4 in primary lung carcinoma. Clin. Cancer Res. 15, 5688-5695 (2009).
24. Wei, D., Kanai, M., Jia, Z., Le, X. & Xie, K. Kruppel-like factor 4 induces p27Kip1 expression in and suppresses the growth and metastasis of human pancreatic cancer cells. Cancer Res. 68, 4631-4639 (2008).
25. Zammarchi, F. et al. KLF4 is a novel candidate tumor suppressor gene in pancreatic ductal carcinoma. Am. J. Pathol. 178, 361-372 (2011).
26. Kong, X. et al. Dysregulated expression of FOXM1 isoforms drive progression of pancreatic cancer. Cancer Res. 69, 3987-3996 (2013).
27. Wei, D. et al. KLF4alpha up-regulation promotes cell cycle progression and reduces survival time of patients with pancreatic cancer. Gastroenterology 139, 2135-2145 (2010).
28. DiFeo, A., Martignetti, J. A. & Narla, G. The role of KLF6 and its splice variants in cancer therapy. Drug Resist. Updat. 12, 1-7 (2009).
29. Yoon, H. S., Chen, X. & Yang, V. W. Kruppel-like factor 4 mediates p53-dependent G1/S cell cycle arrest in response to DNA damage. J. Biol. Chem. 278, 2101-2105 (2003).
30. Shie, J. L., Chen, Z. Y., Fu, M., Pestell, R. G. & Tseng, C. C. Gut-enriched Kruppel-like factor represses cyclin D1 promoter activity through Sp1 motif. Nucleic Acids Res. 28, 2969-2976 (2000).
31. Yoon, H. S. & Yang, V. W. Requirement of Kruppel-like factor 4 in preventing entry into mitosis following DNA damage. J. Biol. Chem. 279, 5035-5041 (2004).
32. Yoon, H. S. et al. Kruppel-like factor 4 prevents centrosome amplification following gamma-irradiation-induced DNA damage. Oncogene 24, 4017-4025 (2005).
33. Evans, P. M. et al. Kruppel-like factor 4 is acetylated by p300 and regulates gene transcription via modulation of histone acetylation. J. Biol. Chem. 282, 33994-34002 (2007). This article highlights the role of cofactors and epigenetic changes in KLF4 function.
34. Katz, J. P. et al. Loss of Klf4 in mice causes altered proliferation and differentiation and precancerous changes in the adult stomach. Gastroenterology 128, 935-945 (2005).
35. Li, Q. et al. Disruption of Klf4 in villin-positive gastric progenitor cells promotes formation and progression of tumors of the antrum in mice. Gastroenterology 142, 531-542 (2012). Disruption of KLF4 in a putative gastric stem cell population leads to gastric cancer.
36. Tetreault, M. P. et al. Esophageal squamous cell dysplasia and delayed differentiation with deletion of kruppel-like factor 4 in murine esophagus. Gastroenterology 139, 171-181 (2010).
37. Akaogi, K. et al. KLF4 suppresses estrogen-dependent breast cancer growth by inhibiting the transcriptional activity of ERalpha. Oncogene 28, 2894-2902 (2009).
38. Yori, J. L. et al. Kruppel-like factor 4 inhibits tumorigenic progression and metastasis in a mouse model of breast cancer. Neoplasia 13, 601-610 (2011).
39. Rowland, B. D. & Peeper, D. S. KLF4, 21 and context-dependent opposing forces in cancer. Nature Rev. Cancer 6, 11-23 (2006).
40. Hu, D., Zhou, Z., Davidson, N. E., Huang, Y. & Wan, Y. Novel insight into KLF4 proteolytic regulation in estrogen receptor signaling and breast carcinogenesis. J. Biol. Chem. 287, 13584-13597 (2012).
41. Chen, C. et al. KLF5 promotes cell proliferation and tumorigenesis through gene regulation and the TSU-Pr1 human bladder cancer cell line. Int. J. Cancer 118, 1346-1355 (2006).
42. Mori, A. et al. Up-regulation of Kruppel-like factor 5 in pancreatic cancer is promoted by interleukin-1beta signaling and hypoxia-inducible factor-1alpha. Mol. Cancer Res. 7, 1390-1398 (2009).
43. Yagi, N. et al. A nanoparticle system specifically designed to deliver short interfering RNA inhibits tumor growth in vivo. Cancer Res. 69, 6531-6538 (2009).
44. Nandan, M. O. et al. Kruppel-like factor 5 mediates cellular transformation during oncogenic KRAS-induced intestinal tumorigenesis. Gastroenterology 134, 120-130 (2008).
45. McConnell, B. B. et al. Haploinsufficiency of Kruppel-like factor 5 rescues the tumor-initiating effect of the Apc(Min) mutation in the intestine. Cancer Res. 69, 4125-4133 (2009). Haploinsufficiency of Klf5 results in a remarkable 96% reduction in the number of intestinal adenomas in ApcMin mice.
46. Nandan, M. O. et al. Kruppel-like factor 5 is a crucial mediator of intestinal tumorigenesis in mice harboring combined ApcMin and KRASV12 mutations. Mol. Cancer 9, 63 (2010).
47. Liu, R., Zhou, Z., Zhao, D. & Chen, C. The induction of KLF5 transcription factor by progesterone contributes to progesterone-induced breast cancer cell proliferation and dedifferentiation. Mol. Endocrinol. 25, 1137-1144 (2011).
48. Takagi, K. et al. Kruppel-like factor 5 in human breast carcinoma: a potent prognostic factor induced by androgens. Endocr. Relat. Cancer 19, 741-750 (2012).
49. Bateman, N. W., Tan, D., Pestell, R. G., Black, J. D. & Black, A. R. Intestinal tumor progression is associated with altered function of KLF5. J. Biol. Chem. 279, 12093-12101 (2004). KLF5 function is highly context dependent, a feature common to many KLFs.
50. Edlund, K. et al. Data-driven unbiased curation of the TP53 tumor suppressor gene mutation database and validation by ultradeep sequencing of human tumors. Proc. Natl Acad. Sci. USA 109, 9551-9556 (2012).
51. Du, J. X., Bialkowska, A. B., McConnell, B. B. & Yang, V. W. SUMOylation regulates nuclear localization of Kruppel-like factor.J. Biol. Chem. 283, 31991-32002 (2008).
52. Oishi, Y. et al. SUMOylation of Kruppel-like transcription factor 5 acts as a molecular switch in transcriptional programs of lipid metabolism involving PPAR-delta. Nature Med. 14, 656-666 (2008).
53. Chen, C. et al. Human Kruppel-like factor 5 is a target of the E3 ubiquitin ligase WWP1 for proteolysis in epithelial cells. J. Biol. Chem. 280, 41553-41561 (2005).
54. Zhao, D., Zheng, H. Q., Zhou, Z. & Chen, C. The Fbw7 tumor suppressor targets KLF5 for ubiquitin-mediated degradation and suppresses breast cell proliferation. Cancer Res. 70, 4728-4738 (2010).
55. Kremer-Tal, S. et al. Frequent inactivation of the tumor suppressor Kruppel-like factor 6 (KLF6) in hepatocellular carcinoma. Hepatology 40, 1047-1052 (2004).
56. Narla, G. et al. KLF6, a candidate tumor suppressor gene mutated in prostate cancer. Science 294, 2563-2566 (2001). KLF6 is a putative tumour suppressor in prostate cancer.
57. Reeves, H. L. et al. Kruppel-like factor 6 (KLF6) is a tumor-suppressor gene frequently inactivated in colorectal cancer. Gastroenterology 126, 1090-1103 (2004).
58. Narla, G. et al. Targeted inhibition of the KLF6 splice variant, KLF6 SV1, suppresses prostate cancer cell growth and spread. Cancer Res. 65, 5761-5768 (2005).
59. Teixeira, M. S. et al. KLF6 allelic loss is associated with tumor recurrence and markedly decreased survival in head and neck squamous cell carcinoma. Int. J. Cancer 121, 1976-1983 (2007).
60. Li, D. et al. Regulation of Kruppel-like factor 6 tumor suppressor activity by acetylation. Cancer Res. 65, 9216-9225 (2005).
61. Lang, U. E. et al. GSK3beta phosphorylation of the KLF6 tumor suppressor promotes its transactivation of p21. Oncogene http://dx.doi.org/10.1038/onc. 2012.457 (2012).
62. Tahara, E., Kadara, H., Lacroix, L., Lotan, D. & Lotan, R. Activation of protein kinase C by phorbol 12-myristate 13-acetate suppresses the growth of lung cancer cells through KLF6 induction. Cancer Biol. Ther. 8, 801-807 (2009).
63. Sangodkar, J. et al. Targeted reduction of KLF6-SV1 restores chemotherapy sensitivity in resistant lung adenocarcinoma. Lung Cancer 66, 292-297 (2009).
64. Narla, G. et al. A germline DNA polymorphism enhances alternative splicing of the KLF6 tumor suppressor gene and is associated with increased prostate cancer risk. Cancer Res. 65, 1213-1222 (2005).
65. Vetter, D. et al. Enhanced hepatocarcinogenesis in mouse models and human hepatocellular carcinoma by coordinate KLF6 depletion and increased messenger RNA splicing. Hepatology 56, 1361-1370 (2012).
66. Hanoun, N. et al. The SV2 variant of KLF6 is down-regulated in hepatocellular carcinoma and displays anti-proliferative and pro-apoptotic functions. J. Hepatol 53, 880-888 (2010).
67. Munoz, U. et al. Hepatocyte growth factor enhances alternative splicing of the Kruppel-like factor 6 (KLF6) tumor suppressor to promote growth through SRSF1. Mol. Cancer Res. 10, 1216-1227 (2012).
68. Yea, S. et al. Ras promotes growth by alternative splicing-mediated inactivation of the KLF6 tumor suppressor in hepatocellular carcinoma. Gastroenterology 134, 1521-1531 (2008).
69. Song, K. D., Kim, D. J., Lee, J. E., Yun, C. H. & Lee, W. K. KLF10, transforming growth factor-beta-inducible early gene 1, acts as a tumor suppressor. Biochem. Biophys. Res. Commun. 419, 388-394 (2012).
70. Nakamura, Y. et al. Kruppel-like factor 12 plays a significant role in poorly differentiated gastric cancer progression. Int. J. Cancer 125, 1859-1867 (2009).
71. Henson, B. J. & Gollin, S. M. Overexpression of KLF13 and FGFR3 in oral cancer cells. Cytogenet. Genome Res. 128, 192-198 (2010).
72. Nemer, M. & Horb, M. E. The KLF family of transcriptional regulators in cardiomyocyte proliferation and differentiation. Cell Cycle 6, 117-121 (2007).
73. Clevers, H. Wnt/β-Catenin Signaling in Development and Disease. Cell 127, 469-480 (2006).
74. Sellak, H., Wu, S. & Lincoln, T. M. KLF4 and SOX9 transcription factors antagonize β-catenin and inhibit TCF-activity in cancer cells. Biochim. Biophys. Acta (BBA)-Mol. Cell Res. 1823, 1666-1675 (2012).
75. Evans, P. M., Chen, X., Zhang, W. & Liu, C. KLF4 interacts with beta-catenin/TCF4 and blocks p300/CBP recruitment by beta-catenin. Mol. Cell. Biol. 30, 372-381 (2010).
76. Ghaleb, A. M. et al. Haploinsufficiency of Kruppel-like factor 4 promotes adenomatous polyposis coli dependent intestinal tumorigenesis. Cancer Res. 67, 7147-7154 (2007).
77. Wei, D. et al. Drastic down-regulation of Kruppel-like factor 4 expression is critical in human gastric cancer development and progression. Cancer Res. 65, 2746-2754 (2005).
78. McConnell, B. B. et al. Kruppel-like factor 5 is important for maintenance of crypt architecture and barrier function in mouse intestine. Gastroenterology 141, 1302-1313, e1-6 (2011).
79. DiFeo, A. et al. E-cadherin is a novel transcriptional target of the KLF6 tumor suppressor. Oncogene 25, 6026-6031 (2006).
80. Kremer-Tal, S. et al. Downregulation of KLF6 is an early event in hepatocarcinogenesis, and stimulates proliferation while reducing differentiation. J. Hepatol 46, 645-654 (2007).
81. Lahiri, S. K. & Zhao, J. Kruppel-like factor 8 emerges as an important regulator of cancer. Am. J. Transl. Res. 4, 357-363 (2012).
82. Yang, T. et al. Kruppel-like factor 8 is a new Wnt/beta-catenin signaling target gene and regulator in hepatocellular carcinoma. PLoS ONE 7, e39668 (2012).
83. Schnell, O. et al. Kruppel-like factor 8 (KLF8) is expressed in gliomas of different WHO grades and is essential for tumor cell proliferation. PLoS ONE 7, e30429 (2012).
84. Chen, G. et al. Lentivirus-mediated gene silencing of KLF8 reduced the proliferation and invasion of gastric cancer cells. Mol. Biol. Rep. 39, 9809-9815 (2012).
85. Fernandez-Zapico, M. E. et al. A functional family-wide screening of SP/KLF proteins identifies a subset of suppressors of KRAS-mediated cell growth. Biochem. J. 435, 529-537 (2011).
86. Nandan, M. O. et al. Kruppel-like factor 5 mediates the transforming activity of oncogenic H-Ras. Oncogene 23, 3404-3413 (2004).
87. Yang, Y., Goldstein, B. G., Nakagawa, H. & Katz, J. P. Kruppel-like factor 5 activates MEK/ERK signaling via EGFR in primary squamous epithelial cells. FASEB J. 21, 543-550 (2007).
88. Huh, S. J. et al. KLF6 gene and early melanoma development in a collagen I-rich extracellular environment. J. Natl Cancer Inst. 102, 1131-1147 (2010).
89. Simmen, R. C. et al. The emerging role of Kruppel-like factors in endocrine-responsive cancers of female reproductive tissues. J. Endocrinol. 204, 223-231 (2010).
90. Chen, C., Bhalala, H. V., Qiao, H. & Dong, J. T. A possible tumor suppressor role of the KLF5 transcription factor in human breast cancer. Oncogene 21, 6567-6572 (2002).
91. Zheng, H. Q. et al. Kruppel-like factor 5 promotes breast cell proliferation partially through upregulating the transcription of fibroblast growth factor binding protein Oncogene 28, 3702-3713 (2009).
92. Guo, P. et al. Estrogen-induced interaction between KLF5 and estrogen receptor (ER) suppresses the function of ER in ER-positive breast cancer cells. Int. J. Cancer 126, 81-89 (2010).
93. Nakajima, Y. et al. Estrogen regulates tumor growth through a nonclassical pathway that includes the transcription factors ERbeta and KLF5. Sci Signal 4, ra22 (2011). Oestrogens and antioestrogens modulate prostate tumour growth through ERβ-mediated regulation of KLF5.
94. Zhao, K. W. et al. Oestrogen causes degradation of KLF5 by inducing the E3 ubiquitin ligase EFP in ER-positive breast cancer cells. Biochem. J. 437, 323-333 (2011).
95. Liu, J. et al. KLF6 inhibits estrogen receptor-mediated cell growth in breast cancer via a c-Src-mediated pathway. Mol. Cell Biochem. 335, 29-35 (2010).
96. Kumar, N. S. et al. Selective down-regulation of progesterone receptor isoform B in poorly differentiated human endometrial cancer cells: implications for unopposed estrogen action. Cancer Res. 58, 1860-1865 (1998).
97. Zhang, X. L. et al. Selective interactions of Kruppel-like factor 9/basic transcription element-binding protein with progesterone receptor isoforms A and B determine transcriptional activity of progesterone-responsive genes in endometrial epithelial cells. J. Biol. Chem. 278, 21474-21482 (2003).
98. Velarde, M. C., Zeng, Z., McQuown, J. R., Simmen, F. A. & Simmen, R. C. Kruppel-like factor 9 is a negative regulator of ligand-dependent estrogen receptor alpha signaling in Ishikawa endometrial adenocarcinoma cells. Mol. Endocrinol. 21, 2988-3001 (2007).
99. Simmons, C. D. et al. Kruppel-like factor 9 loss-of-expression in human endometrial carcinoma links altered expression of growth-regulatory genes with aberrant proliferative response to estrogen. Biol. Reprod. 85, 378-385 (2011).
100. Simmen, F. A., Su, Y., Xiao, R., Zeng, Z. & Simmen, R. C. The Kruppel-like factor 9 (KLF9) network in HEC-1-A endometrial carcinoma cells suggests the carcinogenic potential of dys-regulated KLF9 expression. Reprod. Biol. Endocrinol. 6, 41 (2008).
101. Ray, S. & Pollard, J. W. KLF15 negatively regulates estrogen-induced epithelial cell proliferation by inhibition of DNA replication licensing. Proc. Natl Acad. Sci. 109, E1334-E1343 (2012).
102. Goldstein, B. G. et al. Overexpression of Kruppel-like factor 5 in esophageal epithelia in vivo leads to increased proliferation in basal but not suprabasal cells. Am. J. Physiol. Gastrointest Liver Physiol. 292, G1784-1792 (2007).
103. Ikushima, H. & Miyazono, K. TGF-β signalling: a complex web in cancer progression. Nature Rev. Cancer 10, 415-424 (2010).
104. Guo, P. et al. Pro-proliferative factor KLF5 becomes anti-proliferative in epithelial homeostasis upon signaling-mediated modification. J. Biol. Chem. 284, 6071-6078 (2009). TGFA complex web in canc can alter KLF5 function via signalling-mediated post-translational modification.
105. Guo, P. et al. Opposing effects of KLF5 on the transcription of MYC in epithelial proliferation in the context of transforming growth factor beta. J. Biol. Chem. 284, 28243-28252 (2009).
106. Jiang, L. et al. Down-regulation of stathmin is required for TGF-beta inducible early gene 1 induced growth inhibition of pancreatic cancer cells. Cancer Lett. 274, 101-108 (2009).
107. Jiang, L. et al. Transactivation of the TIEG1 confers growth inhibition of transforming growth factor-beta-susceptible hepatocellular carcinoma cells. World J. Gastroenterol. 18, 2035-2042 (2012).
108. Buck, A. et al. The tumor suppressor KLF11 mediates a novel mechanism in transforming growth factor beta-induced growth inhibition that is inactivated in pancreatic cancer. Mol. Cancer Res. 4, 861-872 (2006).
109. Zhang, J. S. et al. A conserved alpha-helical motif mediates the interaction of Sp1-like transcriptional repressors with the corepressor mSin3A. Mol. Cell. Biol. 21, 5041-5049 (2001).
110. Ohashi, S. et al. A NOTCH3-mediated squamous cell differentiation program limits expansion of EMT-competent cells that express the ZEB transcription factors. Cancer Res. 71, 6836-6847 (2011).
111. Miele, L. Notch signaling. Clin. Cancer Res. 12, 1074-1079 (2006).
112. Lambertini, C., Pantano, S. & Dotto, G. P. Differential control of Notch1 gene transcription by Klf4 and Sp3 transcription factors in normal versus cancer-derived keratinocytes. PLoS ONE 5, e10369 (2010).
113. Liu, Z. et al. Epithelial transformation by KLF4 requires Notch1 but not canonical Notch1 signaling. Cancer Biol. Ther. 8, 1840-1851 (2009).
114. Ghaleb, A. M., Aggarwal, G., Bialkowska, A. B., Nandan, M. O. & Yang, V. W. Notch inhibits expression of the Kruppel-like factor 4 tumor suppressor in the intestinal epithelium. Mol. Cancer Res. 6, 1920-1927 (2008).
115. Dang, D. T. et al. Overexpression of Kruppel-like factor 4 in the human colon cancer cell line RKO leads to reduced tumorigenecity. Oncogene 22, 3424-3430 (2003).
116. Lin, Z. S., Chu, H. C., Yen, Y. C., Lewis, B. C. & Chen, Y. W. Kruppel-like factor 4, a tumor suppressor in hepatocellular carcinoma cells reverts epithelial mesenchymal transition by suppressing slug expression. PLoS ONE 7, e43593 (2012).
117. Foster, K. W. et al. Induction of KLF4 in basal keratinocytes blocks the proliferation-differentiation switch and initiates squamous epithelial dysplasia. Oncogene 24, 1491-1500 (2005).
118. Li, J. et al. Deficiency of the Kruppel-like factor KLF4 correlates with increased cell proliferation and enhanced skin tumorigenesis. Carcinogenesis 33, 1239-1246 (2012).
119. Tetreault, M. P. et al. Klf4 overexpression activates epithelial cytokines and inflammation-mediated esophageal squamous cell cancer in mice. Gastroenterology 139, 2124-2134 (2010). KLF4 in epithelial cells recruits immune cells in an NF-κB-dependent manner resulting in oesophageal dysplasia and cancers. These findings have important implications for the regulation of the microenvironment by KLF4 and other KLFs.
120. Humbert, M. et al. Deregulated expression of Kruppel-like factors in acute myeloid leukemia. Leuk. Res. 35, 909-913 (2011).
121. Turner, J. & Crossley, M. Basic Krüppel-like factor functions within a network of interacting haematopoietic transcription factors. Int. J. Biochem. Cell Biol. 31, 1169-1174 (1999).
122. Kharas, M. G. et al. KLF4 suppresses transformation of pre-B cells by ABL oncogenes. Blood 109, 747-755 (2007).
123. Tarocchi, M. et al. Carcinogen-induced hepatic tumors in KLF6+/- mice recapitulate aggressive human hepatocellular carcinoma associated with p53 pathway deregulation. Hepatology 54, 522-531 (2011).
124. Kimmelman, A. C. et al. Suppression of glioblastoma tumorigenicity by the Kruppel-like transcription factor KLF6. Oncogene 23, 5077-5083 (2004).
125. Lu, H. et al. Transformation of human ovarian surface epithelial cells by Kruppel-like factor Oncogene http://dx.doi.org/10.1038/onc.2012.545 (2012).
126. Holland, A. J. & Cleveland, D. W. The deubiquitinase USP44 is a tumor suppressor that protects against chromosome missegregation. J. Clin. Invest. 122, 4325-4328 (2012).
127. Wang, X. & Zhao, J. KLF8 transcription factor participates in oncogenic transformation. Oncogene 26, 456-461 (2007).
128. Cai, X. D. et al. Reduced expression of Kruppel-like factor 17 is related to tumor growth and poor prognosis in lung adenocarcinoma. Biochem. Biophys. Res. Commun. 418, 67-73 (2012).
129. Senderowicz, A. M. Targeting cell cycle and apoptosis for the treatment of human malignancies. Curr. Opin. Cell Biol. 16, 670-678 (2004).
130. Li, Z. et al. KLF4 promotes hydrogen-peroxide-induced apoptosis of chronic myeloid leukemia cells involving the bcl-2/bax pathway. Cell Stress Chaperones 15, 905-912 (2010).
131. Mohan, N., Ai, W., Chakrabarti, M., Banik, N. L. & Ray, S. K. KLF4 overexpression and apigenin treatment down regulated anti-apoptotic Bcl-2 proteins and matrix metalloproteinases to control growth of human malignant neuroblastoma SK-N-DZ and IMR-32 cells. Mol. Oncol. 7, 464-474 (2012).
132. Zhang, G. et al. Kruppel-like factor 4 represses transcription of the survivin gene in esophageal cancer cell lines. Biol. Chem. 390, 463-469 (2009).
133. Yang, Y., Goldstein, B. G., Chao, H. H. & Katz, J. P. KLF4 and KLF5 regulate proliferation, apoptosis and invasion in esophageal cancer cells. Cancer Biol. Ther. 4, 1216-1221 (2005).
134. Ghaleb, A. M., Katz, J. P., Kaestner, K. H., Du, J. X. & Yang, V. W. Kruppel-like factor 4 exhibits antiapoptotic activity following gamma-radiation-induced DNA damage. Oncogene 26, 2365-2373 (2007).
135. Zhao, Y. et al. Kruppel-like factor 5 modulates p53-independent apoptosis through Pim1 survival kinase in cancer cells. Oncogene 27, 1-8 (2008).
136. Liu, R., Zheng, H. Q., Zhou, Z., Dong, J. T. & Chen, C. KLF5 promotes breast cell survival partially through fibroblast growth factor-binding protein 1-pERK-mediated dual specificity MKP-1 protein phosphorylation and stabilization. J. Biol. Chem. 284, 16791-16798 (2009).
137. Zhu, N. et al. KLF5 Interacts with p53 in regulating survivin expression in acute lymphoblastic leukemia. J. Biol. Chem. 281, 14711-14718 (2006).
138. Tarapore, R. S., Yang, Y. & Katz, J. P. Restoring KLF5 in esophageal squamous cell cancer cells activates the JNK pathway leading to apoptosis and reduced cell survival. Neoplasia 15, 472-480 (2013).
139. Ito, G. et al. Kruppel-like factor 6 is frequently down-regulated and induces apoptosis in non-small cell lung cancer cells. Cancer Res. 64, 3838-3843 (2004).
140. Jianwei, Z., Enzhong, B., Fan, L., Jian, L. & Ning, A. Effects of Kruppel-like factor 6 on osteosarcoma cell biological behavior. Tumour Biol. 34, 1097-1105 (2013).
141. Huang, X., Li, X. & Guo, B. KLF6 induces apoptosis in prostate cancer cells through up-regulation of ATF3. J. Biol. Chem. 283, 29795-29801 (2008).
142. Sirach, E. et al. KLF6 transcription factor protects hepatocellular carcinoma-derived cells from apoptosis. Cell Death Differ. 14, 1202-1210 (2007).
143. Difeo, A. et al. KLF6-SV1 is a novel antiapoptotic protein that targets the BH3-only protein NOXA for degradation and whose inhibition extends survival in an ovarian cancer model. Cancer Res. 69, 4733-4741 (2009).
144. Liu, X. et al. KLF6 loss of function in human prostate cancer progression is implicated in resistance to androgen deprivation. Am. J. Pathol. 181, 1007-1016 (2012).
145. Mannava, S. et al. KLF9 is a novel transcriptional regulator of bortezomib-and LBH589-induced apoptosis in multiple myeloma cells. Blood 119, 1450-1458 (2012).
146. Tachibana, I. et al. Overexpression of the TGFbeta-regulated zinc finger encoding gene, TIEG, induces apoptosis in pancreatic epithelial cells. J. Clin. Invest. 99, 2365-2374 (1997).
147. Hsu, C. F. et al. Klf10 induces cell apoptosis through modulation of BI-1 expression and Ca2+ homeostasis in estrogen-responding adenocarcinoma cells. Int. J. Biochem. Cell Biol. 43, 666-673 (2011).
148. Chang, H. S., Lin, C. H., Yang, C. H., Liang, Y. J. & Yu, W. C. The human papillomavirus-16 (HPV-16) oncoprotein E7 conjugates with and mediates the role of the transforming growth factor-beta inducible early gene 1 (TIEG1) in apoptosis. Int. J. Biochem. Cell Biol. 42, 1831-1839 (2010).
149. Thiery, J. P., Acloque, H., Huang, R. Y. J. & Nieto, M. A. Epithelial-Mesenchymal Transitions in Development and Disease. Cell 139, 871-890 (2009).
150. Yori, J. L., Johnson, E., Zhou, G., Jain, M. K. & Keri, R. A. Kruppel-like factor 4 inhibits epithelial-to-mesenchymal transition through regulation of E-cadherin gene expression. J. Biol. Chem. 285, 16854-16863 (2010).
151. Liu, Y. N. et al. Critical and reciprocal regulation of KLF4 and SLUG in transforming growth factor beta-initiated prostate cancer epithelial-mesenchymal transition. Mol. Cell. Biol. 32, 941-953 (2012).
152. Tian, Y. et al. MicroRNA-10b promotes migration and invasion through KLF4 in human esophageal cancer cell lines. J. Biol. Chem. 285, 7986-7994 (2010).
153. Shimamura, T. et al. A novel network profiling analysis reveals system changes in epithelial-mesenchymal transition. PLoS ONE 6, e20804 (2011).
154. Hatami, R. et al. KLF6-SV1 Drives Breast Cancer Metastasis and Is Associated with Poor Survival. Sci Transl Med 5, 169ra12 (2013). This paper and reference 58 show that the KLF6 splice variant KLF6-SV1 promotes breast and prostate cancer progression. Thus, targeting of KLF6-SV1 may be a useful approach for cancer therapy.
155. Narla, G. et al. KLF6-SV1 overexpression accelerates human and mouse prostate cancer progression and metastasis. J. Clin. Invest. 118, 2711-2721 (2008).
156. DiFeo, A. et al. Roles of KLF6 and KLF6-SV1 in ovarian cancer progression and intraperitoneal dissemination. Clin. Cancer Res. 12, 3730-3739 (2006).
157. Lee, U. E. et al. Tumor suppressor activity of KLF6 mediated by downregulation of the PTTG1 oncogene. FEBS Lett. 584, 1006-1010 (2010).
158. Yoon, C. H. et al. PTTG1 oncogene promotes tumor malignancy via epithelial to mesenchymal transition and expansion of cancer stem cell population. J. Biol. Chem. 287, 19516-19527 (2012).
159. Chen, H. et al. A small interfering RNA targeting the KLF6 splice variant, KLF6-SV1, as gene therapy for gastric cancer. Gastr. Cancer 14, 339-352 (2011).
160. Wang, X. et al. KLF8 promotes human breast cancer cell invasion and metastasis by transcriptional activation of MMP9. Oncogene 30, 1901-1911 (2011).
161. Wang, X. et al. Kruppel-like factor 8 induces epithelial to mesenchymal transition and epithelial cell invasion. Cancer Res. 67, 7184-7193 (2007).
162. Li, J. C. et al. Up-regulation of Kruppel-like factor 8 promotes tumor invasion and indicates poor prognosis for hepatocellular carcinoma. Gastroenterology 139, 2146-2157 e12 (2010).
163. Wang, X., Urvalek, A. M., Liu, J. & Zhao, J. Activation of KLF8 transcription by focal adhesion kinase in human ovarian epithelial and cancer cells. J. Biol. Chem. 283, 13934-13942 (2008).
164. Venkov, C. et al. Transcriptional networks in epithelial-mesenchymal transition. PLoS ONE 6, e25354 (2011).
165. Jin, W. et al. TIEG1 inhibits breast cancer invasion and metastasis by inhibition of epidermal growth factor receptor (EGFR) transcription and the EGFR signaling pathway. Mol. Cell. Biol. 32, 50-63 (2012).
166. Subramaniam, M. et al. Tissue, cell type, and breast cancer stage-specific expression of a TGF-beta inducible early transcription factor gene. J. Cell Biochem. 68, 226-236 (1998).
167. Gumireddy, K. et al. KLF17 is a negative regulator of epithelial-mesenchymal transition and metastasis in breast cancer. Nature Cell Biol. 11, 1297-1304 (2009). KLF17 inhibits EMT in breast cancer via transcriptional repression of Id1.
168. Liu, F. Y. et al. Down-regulated KLF17 expression is associated with tumor invasion and poor prognosis in hepatocellular carcinoma. Med. Oncol. 30, 425 (2013).
169. Cao, Z., Sun, X., Icli, B., Wara, A. K. & Feinberg, M. W. Role of Kruppel-like factors in leukocyte development, function, and disease. Blood 116, 4404-4414 (2010).
170. Atkins, G. B. & Jain, M. K. Role of Kruppel-like transcription factors in endothelial biology. Circ. Res. 100, 1686-1695 (2007).
171. Omotehara, F. et al. Vesnarinone, a differentiation inducing drug, directly activates p21(waf1) gene promoter via Sp1 sites in a human salivary gland cancer cell line. Br. J. Cancer 87, 1042-1046 (2002).
172. Uchida, D. et al. Vesnarinone downregulates CXCR4 expression via upregulation of Kruppel-like factor 2 in oral cancer cells. Mol. Cancer 8, 62 (2009).
173. Yu, F. et al. Deficiency of kruppel-like factor KLF4 in mammary tumor cells inhibits tumor growth and pulmonary metastasis and is accompanied by compromised recruitment of myeloid-derived suppressor cells. Int. J. Cancer http://dx.doi. org/10.1002/ijc.28302 (2013).
174. Chanchevalap, S. et al. Kruppel-like factor 5 is an important mediator for lipopolysaccharide-induced proinflammatory response in intestinal epithelial cells. Nucleic Acids Res. 34, 1216-1223 (2006).
175. Zhang, D. Y. & Friedman, S. L. Fibrosis-dependent mechanisms of hepatocarcinogenesis. Hepatology 56, 769-775 (2012).
176. Watanabe, K., Ohnishi, S., Manabe, I., Nagai, R. & Kadowaki, T. KLF6 in nonalcoholic fatty liver disease: role of fibrogenesis and carcinogenesis. Gastroenterology 135, 309-312 (2008).
177. Miele, L. et al. The Kruppel-like factor 6 genotype is associated with fibrosis in nonalcoholic fatty liver disease. Gastroenterology 135, 282-291 e1 (2008).
178. Biswas, S. K. & Mantovani, A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nature Immunol. 11, 889-896 (2010).
179. Liao, X. et al. Kruppel-like factor 4 regulates macrophage polarization. J. Clin. Invest. 121, 2736-2749 (2011).
180. Venuprasad, K. et al. The E3 ubiquitin ligase Itch regulates expression of transcription factor Foxp3 and airway inflammation by enhancing the function of transcription factor TIEG1. Nature Immunol. 9, 245-253 (2008).
181. Cao, Z. et al. Kruppel-like factor KLF10 targets transforming growth factor-beta1 to regulate CD4(+) CD25(-) T cells and T regulatory cells. J. Biol. Chem. 284, 24914-24924 (2009).
182. Chakroborty, D. et al. Dopamine stabilizes tumor blood vessels by up-regulating angiopoietin 1 expression in pericytes and Kruppel-like factor-2 expression in tumor endothelial cells. Proc. Natl Acad. Sci. USA 108, 20730-20735 (2011). KLF2 regulates tumour angiogenesis.
183. Madden, S. L. et al. Vascular gene expression in nonneoplastic and malignant brain. Am. J. Pathol. 165, 601-608 (2004).
184. Tang, D. G. Understanding cancer stem cell heterogeneity and plasticity. Cell Res. 22, 457-472 (2012).
185. Yeo, J. C. & Ng, H. H. The transcriptional regulation of pluripotency. Cell Res. 23, 20-32 (2013).
186. Wong, C. W. et al. Kruppel-like transcription factor 4 contributes to maintenance of telomerase activity in stem cells. Stem Cells 28, 1510-1517 (2010).
187. Hoffmeyer, K. et al. Wnt/beta-catenin signaling regulates telomerase in stem cells and cancer cells. Science 336, 1549-1554 (2012).
188. Leng, Z. et al. Kruppel-like factor 4 acts as an oncogene in colon cancer stem cell-enriched spheroid cells. PLoS ONE 8, e56082 (2013).
189. Yu, F. et al. Kruppel-like factor 4 (KLF4) is required for maintenance of breast cancer stem cells and for cell migration and invasion. Oncogene 30, 2161-2172 (2011).
190. Vaira, V. et al. Regulation of lung cancer metastasis by Klf4-Numb-like signaling. Cancer Res. 73, 2695-2705 (2013).
191. Wellner, U. et al. The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nature Cell Biol. 11, 1487-1495 (2009). miRNA repression of KLF4 and other stemness factors links these factors to EMT and tumorigenicity.
192. Okuda, H. et al. miR-7 suppresses brain metastasis of breast cancer stem-like cells by modulating KLF4. Cancer Res. 73, 1434-1444 (2013).
193. Nagata, S., Hirano, K., Kanemori, M., Sun, L. T. & Tada, T. Self-renewal and pluripotency acquired through somatic reprogramming to human cancer stem cells. PLoS ONE 7, e48699 (2012).
194. Nishi, M. et al. Induction of cells with cancer stem cell properties from nontumorigenic human mammary epithelial cells by defined reprogramming factors. Oncogene http://dx.doi.org/10.1038/onc.2012.614 (2013).
195. Zhang, X., Cruz, F. D., Terry, M., Remotti, F. & Matushansky, I. Terminal differentiation and loss of tumorigenicity of human cancers via pluripotency-based reprogramming. Oncogene 32, 2249-2260 (2013).
196. Miyoshi, N. et al. Defined factors induce reprogramming of gastrointestinal cancer cells. Proc. Natl Acad. Sci. USA 107, 40-45 (2010).
197. Sarig, R. et al. Mutant p53 facilitates somatic cell reprogramming and augments the malignant potential of reprogrammed cells. J. Exp. Med. 207, 2127-2140 (2010). KLF4 overexpression in cells with mutation or loss of p53 yields aggressive tumours, sounding a cautionary note for reprogramming of cancer cells with p53 mutations.
198. Huang, D. et al. Isolation and identification of cancer stem-like cells in esophageal carcinoma cell lines. Stem Cells Dev. 18, 465-473 (2009).
199. Ying, M. et al. Krüppel-like family of transcription factor 9, a differentiation-associated transcription factor, suppresses Notch1 signaling and inhibits glioblastoma-initiating stem cells. Stem Cells 29, 20-31 (2011).
200. Lomberk, G. et al. Sequence-specific recruitment of heterochromatin protein 1 via interaction with Kruppel-like factor 11, a human transcription factor involved in tumor suppression and metabolic diseases. J. Biol. Chem. 287, 13026-13039 (2012).
201. Soufi, A., Donahue, G. & Zaret, K. S. Facilitators and impediments of the pluripotency reprogramming factors' initial engagement with the genome. Cell 151, 994-1004 (2012).
202. Bialkowska, A. B. et al. Identification of small-molecule inhibitors of the colorectal cancer oncogene Kruppel-like factor 5 expression by ultrahigh-throughput screening. Mol. Cancer Ther. 10, 2043-2051 (2011).
203. Sangodkar, J. et al. Targeting the FOXO1/KLF6 axis regulates EGFR signaling and treatment response. J. Clin. Invest. 122, 2637-2651 (2012). This paper, along with studies targeting KLF5, provides proof of concept for therapies targeting specific KLFs in cancer.